Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India
· Delayed Price · Currency is INR 2,117.60
-6.80 (-0.32%)
At close: Mar 9, 2026
Glenmark Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Market Capitalization | 597,588 | 434,866 | 270,463 | 131,124 | 124,718 | 131,124 | Upgrade
|
| Market Cap Growth | 60.06% | 60.79% | 106.27% | 5.14% | -4.88% | 125.75% | Upgrade
|
| Enterprise Value | 582,926 | 434,470 | 315,126 | 164,781 | 152,778 | 150,427 | Upgrade
|
| Last Close Price | 2117.60 | 1537.28 | 954.74 | 461.55 | 436.18 | 456.42 | Upgrade
|
| PE Ratio | 56.11 | 41.53 | - | 44.11 | 13.24 | 13.52 | Upgrade
|
| Forward PE | 25.93 | 26.02 | 26.45 | 10.10 | 10.59 | 12.50 | Upgrade
|
| PS Ratio | 3.62 | 3.25 | 2.14 | 1.13 | 1.01 | 1.20 | Upgrade
|
| PB Ratio | 6.24 | 4.91 | 3.45 | 1.33 | 1.32 | 1.86 | Upgrade
|
| P/TBV Ratio | 7.69 | 5.89 | 4.15 | 1.86 | 1.83 | 2.77 | Upgrade
|
| P/FCF Ratio | - | - | - | 743.80 | 39.15 | 36.78 | Upgrade
|
| P/OCF Ratio | - | - | - | 20.97 | 11.25 | 11.59 | Upgrade
|
| PEG Ratio | 1.11 | 1.25 | 1.12 | 0.63 | 1.71 | 1.14 | Upgrade
|
| EV/Sales Ratio | 3.53 | 3.25 | 2.49 | 1.41 | 1.24 | 1.38 | Upgrade
|
| EV/EBITDA Ratio | 14.12 | 20.04 | 17.22 | 11.53 | 7.99 | 7.74 | Upgrade
|
| EV/EBIT Ratio | 15.10 | 22.78 | 21.80 | 14.48 | 8.30 | 8.77 | Upgrade
|
| EV/FCF Ratio | - | - | - | 934.71 | 47.96 | 42.20 | Upgrade
|
| Debt / Equity Ratio | 0.13 | 0.28 | 0.16 | 0.47 | 0.42 | 0.71 | Upgrade
|
| Debt / EBITDA Ratio | 0.30 | 1.09 | 0.64 | 3.03 | 1.98 | 2.45 | Upgrade
|
| Debt / FCF Ratio | - | - | - | 261.38 | 12.44 | 13.99 | Upgrade
|
| Net Debt / Equity Ratio | -0.15 | 0.09 | -0.05 | 0.35 | 0.27 | 0.54 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.36 | 0.37 | -0.24 | 2.41 | 1.33 | 1.97 | Upgrade
|
| Net Debt / FCF Ratio | - | -0.50 | 0.37 | 195.11 | 7.99 | 10.77 | Upgrade
|
| Asset Turnover | - | 0.88 | 0.75 | 0.64 | 0.75 | 0.72 | Upgrade
|
| Inventory Turnover | - | 1.63 | 1.87 | 1.81 | 1.90 | 1.74 | Upgrade
|
| Quick Ratio | - | 0.94 | 0.75 | 1.06 | 1.08 | 1.00 | Upgrade
|
| Current Ratio | - | 1.56 | 1.28 | 2.10 | 1.77 | 1.75 | Upgrade
|
| Return on Equity (ROE) | - | 12.54% | -20.70% | -0.93% | 12.04% | 14.77% | Upgrade
|
| Return on Assets (ROA) | - | 7.84% | 5.36% | 3.90% | 7.04% | 7.08% | Upgrade
|
| Return on Invested Capital (ROIC) | 31.57% | 16.74% | -700.97% | -3.36% | 11.09% | 11.45% | Upgrade
|
| Return on Capital Employed (ROCE) | - | 18.90% | 16.90% | 8.00% | 14.80% | 15.00% | Upgrade
|
| Earnings Yield | 1.78% | 2.41% | -5.55% | 2.27% | 7.55% | 7.40% | Upgrade
|
| FCF Yield | - | -3.63% | -4.30% | 0.13% | 2.55% | 2.72% | Upgrade
|
| Dividend Yield | 0.24% | 0.16% | 0.26% | 0.54% | 0.57% | 0.55% | Upgrade
|
| Payout Ratio | - | 6.73% | - | 23.68% | 9.84% | 7.26% | Upgrade
|
| Buyback Yield / Dilution | -0.04% | -0.01% | -0.00% | - | - | - | Upgrade
|
| Total Shareholder Return | 0.19% | 0.15% | 0.26% | 0.54% | 0.57% | 0.55% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.